Medicare Part D in 2026: The New $2,100 Cap and Why Institutional Plans Are Growing

What’s changing in Part D for 2026

For 2026, Medicare Part D’s redesign under the Inflation Reduction Act has already reset the safety net that caps what beneficiaries pay out of pocket for prescription drugs: the threshold that triggers zero-cost-sharing catastrophic coverage rose to $2,100, up from $2,000 in 2025, under the Centers for Medicare & Medicaid Services’ final CY2026 Part D redesign instructions. At the same time, the broader Medicare Advantage market that many beneficiaries use to get that drug coverage has kept shrinking in plan count even as a specific slice of it — Special Needs Plans, including plans built for nursing home and long-term-care residents — kept growing. Both threads matter to anyone tracking what a Medicare drug benefit actually costs in 2026, and they matter especially to families managing coverage for a relative who needs institutional-level care.

Who Institutional Special Needs Plans serve

One corner of Medicare Advantage exists specifically for people who need a nursing-home level of care: Institutional Special Needs Plans, or I-SNPs. CMS defines an I-SNP as a Medicare Advantage plan restricted to beneficiaries who, for 90 days or longer, have had or are expected to need the level of care provided in a long-term-care skilled nursing facility, a nursing facility, an intermediate care facility for individuals with intellectual disabilities, or an inpatient psychiatric facility. That is a narrower population than Medicare Advantage as a whole — most enrollees never need that level of care — which is exactly why I-SNPs exist as a distinct plan type rather than a feature bolted onto a standard plan. Their provider networks, care coordination, and drug formularies are built around residents who are already living in, or functionally require, an institutional setting.

The $2,100 out-of-pocket cap

The headline Part D change for 2026 is the higher catastrophic threshold. Once a beneficiary’s out-of-pocket drug spending reaches $2,100, Part D cost-sharing for covered drugs drops to zero for the rest of the year — a hard annual ceiling that replaced Part D’s older, more complicated cost-sharing structure. That $2,100 figure is $100 higher than the $2,000 cap that applied in 2025, part of a structure Congress built into the Inflation Reduction Act specifically to phase in, and then index, a real out-of-pocket cap for the first time in the drug benefit’s history.

Analysis: a $100 year-over-year increase sounds modest, but the number that matters more than the cap’s exact level is that a fixed dollar ceiling exists at all — before the IRA redesign, Part D had no true out-of-pocket cap, only percentage-based cost-sharing tiers that could add up indefinitely for someone on expensive medications. For most people the cap is a backstop they’ll rarely touch; for someone managing several chronic conditions with high-cost drugs, it’s the number that decides whether a bad year is merely expensive or genuinely unaffordable.

Why many nursing home residents pay nothing

The $2,100 cap matters mainly to people who pay Part D cost-sharing at all — and a large share of nursing facility residents don’t. Full-benefit dual-eligible beneficiaries — people enrolled in both Medicare and Medicaid — who are institutionalized, meaning confirmed nursing-facility residents under their state’s Medicaid rules, generally owe $0 in Part D premiums and $0 in cost-sharing for covered drugs. That protection runs through the Extra Help/Low-Income Subsidy program, layered on top of standard Part D rules specifically for beneficiaries with limited income and resources.

Analysis: this is why the 2026 cap increase and I-SNP enrollment trends can seem to point in different directions at once. The out-of-pocket cap is the number that gets the headlines, but for the institutionalized dual-eligible population that I-SNPs are built to serve, the cap is often close to irrelevant — their cost-sharing was already zero. The more consequential number for that group is usually whether their state has correctly confirmed institutional status for Medicaid purposes, since that status is what triggers the $0 drug cost-sharing in the first place.

Fewer plans overall, but more SNP options

The overall Medicare Advantage market got smaller for 2026: insurers offered 3,373 individual Medicare Advantage plans nationwide, a 9% drop — 346 fewer plans — than in 2025. Special Needs Plans moved in the opposite direction as a category, totaling 1,721 plans: 1,019 Dual Eligible SNPs, 548 Chronic Condition SNPs, and 154 Institutional SNPs. The I-SNP count itself actually declined slightly, from 160 in 2025 to 154 in 2026.

Analysis: a slight dip in I-SNP plan count doesn’t mean the institutional-care market is shrinking — enrollment in institutional and institutional-equivalent Medicare Advantage plans has kept climbing even as the number of I-SNPs offered has edged down since 2023, per Milliman’s review of CMS plan filing data. Read together with ATI Advisory’s observation that enrollment has been shifting toward smaller, specialized I-SNP carriers, the pattern looks like consolidation rather than retreat: fewer, more focused I-SNP operators covering more residents each, not insurers abandoning the institutional-care segment.

What it means for families choosing coverage

The clearest sign that Special Needs Plans are gaining ground, not losing it, is enrollment: SNPs — the category that includes I-SNPs alongside Dual Eligible and Chronic Condition plans — reached more than 8 million enrollees as of February 2026, up nearly 900,000 from a year earlier and now accounting for about 23% of total Medicare Advantage enrollment. SNPs were the primary driver of Medicare Advantage’s enrollment growth in 2026, even as the overall count of individual MA plans on offer fell.

Practical: for a family evaluating coverage for a relative who needs, or is expected to need, 90-plus days of nursing-facility-level care, the plan-count headline matters less than three concrete questions: whether an I-SNP is offered in the facility’s service area, whether the resident qualifies as a full-benefit dual eligible with confirmed institutional status (which is what unlocks $0 cost-sharing), and, if not, how the $2,100 out-of-pocket cap will apply to their specific drug regimen this year. Those three answers matter more to an actual household budget than either the national plan count or the cap figure on its own.